PALVELLA THERAPEUTICS, INC. (PVLA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PVLA currently has 13.1M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 594.0% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 13.1M shares outstanding |
13M | 0 |
| Mar 31, 2026 |
10-K filing | 14.3M shares outstanding |
14M | 0 |
| Jan 02, 2026 |
S-3 filing: Palvella Therapeutics, Inc. may offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, units and rights from time to time in one or more offerings. |
11M | 0 |
| Nov 12, 2025 |
10-Q filing | 11.1M shares outstanding |
11M | 0 |
| May 15, 2025 |
10-Q filing | 11.0M shares outstanding |
11M | 0 |
| Mar 31, 2025 |
10-K filing | 11.0M shares outstanding |
11M | 0 |
| Jan 14, 2025 |
S-1/A filing: This S-1/A filing relates to the proposed offer and resale of up to 3,168,048 shares of common stock and 2,466,456 shares of common stock underlying pre-funded warrants by selling stockholders. |
8.3M | 0 |
| Dec 31, 2024 |
S-1 filing: This S-1 filing is for the proposed offer and resale of up to 3,168,048 shares of common stock and 2,466,456 shares of common stock underlying pre-funded warrants by selling stockholders. |
1.3M | 5.3M |
| Nov 13, 2024 |
10-Q filing | 1.3M shares outstanding |
1.3M | 0 |
| Aug 14, 2024 |
10-Q filing | 1.3M shares outstanding |
1.3M | 0 |
| May 15, 2024 |
10-Q filing | 1.2M shares outstanding |
1.2M | 0 |
| Apr 22, 2024 |
Stock Split
8-K filing: Stock split 1-for-80 | Outstanding: 90,064,000 → 1,236,688 |
1.2M | 0 |
| Mar 29, 2024 |
10-K filing | 90.1M shares outstanding |
90M | 0 |
| Nov 14, 2023 |
10-Q filing | 98.9M shares outstanding |
99M | 0 |
| Aug 10, 2023 |
10-Q filing | 98.9M shares outstanding |
99M | 0 |
| May 11, 2023 |
10-Q filing | 74.5M shares outstanding |
75M | 2.5M |
| Mar 31, 2023 |
10-K filing | 74.2M shares outstanding |
74M | 2.8M |
| Nov 04, 2022 |
10-Q filing | 74.4M shares outstanding |
74M | 2.6M |
| Aug 04, 2022 |
10-Q filing | 74.1M shares outstanding |
74M | 2.9M |
| May 11, 2022 |
10-Q filing | 73.7M shares outstanding |
74M | 3.3M |
| Mar 02, 2022 |
10-K filing | 74.1M shares outstanding |
74M | 2.9M |
| Nov 02, 2021 |
10-Q filing | 67.7M shares outstanding |
68M | 9.3M |
| Aug 05, 2021 |
10-Q filing | 61.9M shares outstanding |
62M | 15M |
| Aug 05, 2021 |
S-3 filing: Pieris Pharmaceuticals, Inc. is filing an S-3 form to register the offering of common stock, preferred stock, and debt securities for a total aggregate amount of $250,000,000. |
67M | 10M |
| May 17, 2021 |
S-3 filing: This prospectus relates to the offer and sale of up to 3,584,230 shares of common stock of Pieris Pharmaceuticals, Inc. by the selling shareholder. |
60M | 3.6M |
| May 17, 2021 |
10-Q filing | 63.3M shares outstanding |
63M | 0 |
| Mar 31, 2021 |
10-K filing | 59.7M shares outstanding |
60M | 0 |
| Nov 04, 2020 |
10-Q filing | 56.0M shares outstanding |
56M | 0 |
| Aug 10, 2020 |
10-Q filing | 52.4M shares outstanding |
52M | 0 |
| May 11, 2020 |
10-Q filing | 52.3M shares outstanding |
52M | 0 |
| Mar 13, 2020 |
10-K filing | 55.2M shares outstanding |
55M | 0 |